Defining the Basis of Fibromuscular Dysplasia (FMD)

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Oct 22, 2013

Keywords

ClinConnect Summary

The clinical trial titled "Defining the Basis of Fibromuscular Dysplasia (FMD)" is studying the underlying biological mechanisms of Fibromuscular Dysplasia and related conditions, such as spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The researchers aim to understand how cells from patients with these conditions differ from those of healthy individuals. This study includes people of all ages and genders, and it’s currently looking for participants who have been diagnosed with FMD, SCAD, or CvAD, as well as healthy individuals who do not have these conditions.

If you or your family member are interested in participating, you should be able to speak either English or Spanish and provide signed consent. Healthy participants will be matched with those who have been diagnosed based on age and gender. This means there will be a good balance between the two groups in the study. Participants can expect to contribute to important research that could help improve our understanding of these vascular conditions. Additionally, individuals with certain health issues, such as serious ongoing diseases or prior organ transplants, may not be eligible to join. Overall, this trial seeks to gather valuable information that could lead to better treatments and outcomes for those affected by FMD and similar disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of any age and freely willing to participate. For patients \< 18 years of age consent will be via parents.
• • Fluency in either English or Spanish.
• • Signed, informed consent
• • For FMD, SCAD or CvAD subjects - a clinical diagnosis of FMD, SCAD or CvAD with fulfillment of standard diagnostic criteria.
• • For healthy controls - no clinical features of FMD, SCAD or CvAD and absence of any major ongoing systemic disease including any condition requiring hospitalization, immune suppression, intravenous or injected medications or that result in functional impairment in the performance of activities of daily living. Healthy controls will be matched to enrolled FMD patients on the basis of gender and approximate age (within a 5 year window of another FMD subject).
• Exclusion Criteria:
• • Patients who have co-morbidities which reduces life expectancy to one year.
• • Patients with any solid organ or hematological transplantation, or those in whom transplantation is considered.
• • Active autoimmune disease.
• • Illicit drug use.
• • HIV positive.
• • Prior malignancy.
• • Any other form of vascular disease, including other arteriopathy coronary artery disease or peripheral vascular disease
• • Family history of arteriopathy other than FMD, SCAD or CvAD (e.g. Ehlers-Danlos syndrome)